Published in Cancer Chemother Pharmacol on February 17, 2015
Pharmacokinetics of Anti-VEGF Agent Aflibercept in Cancer Predicted by Data-Driven, Molecular-Detailed Model. CPT Pharmacometrics Syst Pharmacol (2015) 0.80
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol (2016) 0.75
Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. Oncologist (2015) 0.75
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn (2017) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed (1999) 8.87
PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed (2005) 6.36
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J (2011) 4.60
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42
Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn (2001) 4.25
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J (2009) 3.99
A size standard for pharmacokinetics. Clin Pharmacokinet (1996) 3.44
Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med (2005) 3.31
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res (2005) 3.00
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol (1999) 2.85
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A (2007) 2.19
Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol (2008) 2.13
Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol (2012) 2.11
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol (2013) 2.08
Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn (2008) 1.97
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer (2004) 1.90
Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res (2003) 1.88
The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel (2007) 1.41
Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet (2013) 1.34
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res (2008) 1.32
Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res (2007) 1.28
The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet (2012) 1.22
Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res (2010) 1.22
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol (2009) 1.18
PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST. CPT Pharmacometrics Syst Pharmacol (2013) 1.12
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer (2011) 1.07
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response. Br J Clin Pharmacol (2015) 1.07
Complexation of VEGF with bevacizumab decreases VEGF clearance in rats. Pharm Res (2002) 1.05
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med (2014) 1.02
Theoretical considerations of target-mediated drug disposition models: simplifications and approximations. Pharm Res (2011) 0.97
An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. Ther Drug Monit (2010) 0.94
Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol (1998) 0.92
High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection. Oncol Lett (2012) 0.90
Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol (2013) 0.90
Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn (2010) 0.87
Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res (2014) 0.86
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts. Cancer Chemother Pharmacol (2013) 0.86
Bevacizumab. Oncologist (2010) 0.83
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis Colon Rectum (2011) 0.81
Optimizing outcomes with bevacizumab by better targeting patients and tumors. Oncology (Williston Park) (2009) 0.76
Gene conversion: mechanisms, evolution and human disease. Nat Rev Genet (2007) 4.62
HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Hum Mutat (2002) 3.65
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol (2002) 3.45
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet (2013) 2.91
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res (2009) 2.90
Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med (2006) 2.65
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet (2011) 2.51
Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet (2010) 2.50
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood (2008) 2.26
HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update. Hum Mutat (2007) 2.22
Planning the human variome project: the Spain report. Hum Mutat (2009) 2.22
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol (2007) 1.92
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol (2005) 1.91
Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother (2012) 1.88
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat (2008) 1.82
PhenCode: connecting ENCODE data with mutations and phenotype. Hum Mutat (2007) 1.75
Genomic rearrangements in inherited disease and cancer. Semin Cancer Biol (2010) 1.72
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res (2010) 1.69
The effect of psychosocial factors on breast cancer outcome: a systematic review. Breast Cancer Res (2007) 1.65
Gene conversion causing human inherited disease: evidence for involvement of non-B-DNA-forming sequences and recombination-promoting motifs in DNA breakage and repair. Hum Mutat (2009) 1.64
Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med (2007) 1.58
A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev (2008) 1.55
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry (2013) 1.55
FINDbase: a relational database recording frequencies of genetic defects leading to inherited disorders worldwide. Nucleic Acids Res (2006) 1.43
Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer (2008) 1.43
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Res Treat (2006) 1.43
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer (2008) 1.43
Documentation of inherited disorders and mutation frequencies in the different religious communities in Israel in the Israeli National Genetic Database. Hum Mutat (2007) 1.41
Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol (2008) 1.40
Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J Pharm Biomed Anal (2008) 1.38
Pain and a purple lesion. Am J Med (2006) 1.38
Practical guidelines addressing ethical issues pertaining to the curation of human locus-specific variation databases (LSDBs). Hum Mutat (2010) 1.33
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer (2003) 1.32
RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. J Gen Intern Med (2014) 1.30
Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res (2008) 1.29
Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev (2013) 1.28
Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics (2014) 1.26
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res (2013) 1.23
Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc (2005) 1.20
Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Monit (2009) 1.19
A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer (2006) 1.16
ETHNOS : A versatile electronic tool for the development and curation of national genetic databases. Hum Genomics (2010) 1.15
Financial crisis and austerity measures in Greece: their impact on health promotion policies and public health care. Health Policy (2013) 1.14
Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother (2011) 1.12
Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage (2006) 1.12
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst (2004) 1.10
Capturing all disease-causing mutations for clinical and research use: toward an effortless system for the Human Variome Project. Genet Med (2009) 1.10
Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics (2010) 1.09
Locus-specific database domain and data content analysis: evolution and content maturation toward clinical use. Hum Mutat (2010) 1.08
The cypriot and Iranian National Mutation Frequency Databases. Hum Mutat (2006) 1.08
Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer (2012) 1.08
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response. Br J Clin Pharmacol (2015) 1.07
Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov Disord (2013) 1.07
Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet (2009) 1.07
DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet (2002) 1.07
Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res (2005) 1.06
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat (2011) 1.05
Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol (2009) 1.05
Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer (2013) 1.04
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol (2012) 1.03
Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas. Virchows Arch (2011) 1.03
Developments in FINDbase worldwide database for clinically relevant genomic variation allele frequencies. Nucleic Acids Res (2013) 1.02
A T-to-G transversion at nucleotide -567 upstream of HBG2 in a GATA-1 binding motif is associated with elevated hemoglobin F. Mol Cell Biol (2008) 1.01
Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology (2009) 1.01
Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. Cancer (2004) 1.01
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat (2012) 1.01
POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance? Anticancer Res (2008) 1.01
Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest (2005) 1.00
FINDbase: a worldwide database for genetic variation allele frequencies updated. Nucleic Acids Res (2010) 1.00
Isolation and characterization of hematopoietic transcription factor complexes by in vivo biotinylation tagging and mass spectrometry. Ann N Y Acad Sci (2005) 1.00
Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol (2007) 0.99
Key challenges for next-generation pharmacogenomics: Science & Society series on Science and Drugs. EMBO Rep (2014) 0.99
Erythroid phenotypes associated with KLF1 mutations. Haematologica (2011) 0.99
Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted? Support Care Cancer (2005) 0.98
Hypermethylation-associated transcriptional silencing of E-cadherin in primary sporadic colorectal carcinomas. J Pathol (2002) 0.98
A1ATVar: a relational database of human SERPINA1 gene variants leading to alpha1-antitrypsin deficiency and application of the VariVis software. Hum Mutat (2009) 0.97
Direct-access genetic testing: the view from Europe. Nat Rev Genet (2011) 0.96
Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics (2011) 0.96
Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol (2002) 0.96
Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat (2005) 0.95
A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res (2009) 0.95
VarioML framework for comprehensive variation data representation and exchange. BMC Bioinformatics (2012) 0.95
Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Oncology (2006) 0.95
Large-scale population genetic analysis for hemoglobinopathies reveals different mutation spectra in central Greece compared to the rest of the country. Am J Hematol (2007) 0.95
Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer (2011) 0.94
The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol (2009) 0.94
Epitaxial growth of π-stacked perfluoropentacene on graphene-coated quartz. ACS Nano (2012) 0.94
Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer (2005) 0.93
Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother (2011) 0.93